Cliff Asness's AVIR Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 247,710 shares of Atea Pharmaceuticals, Inc. (AVIR) worth $1.15 M, representing 0.00% of the portfolio. First purchased in 2022-Q1, this medium-term investment has been held for 14 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in AVIR, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2026, adding 201,601 shares. Largest reduction occurred in Q2 2022, reducing 173,178 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Atea Pharmaceuticals (AVIR) Holding Value Over Time
Track share changes against reported price movement
Quarterly Atea Pharmaceuticals (AVIR) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +201,601 | Add 437.23% | 247,710 | $4.65 |
| Q1 2026 | +31,811 | Add 222.49% | 46,109 | $5.38 |
| Q4 2025 | +888 | Add 6.62% | 14,298 | $3.57 |
| Q3 2025 | +13,410 | New Buy | 13,410 | $2.90 |
| Q4 2024 | -13,143 | Sold Out | 0 | $0.00 |
| Q3 2024 | +13,143 | New Buy | 13,143 | $3.35 |
| Q4 2023 | -30,353 | Sold Out | 0 | $0.00 |
| Q3 2023 | -3,237 | Reduce 9.64% | 30,353 | $3.00 |
| Q2 2023 | -103,491 | Reduce 75.50% | 33,590 | $3.74 |
| Q1 2023 | -13,807 | Reduce 9.15% | 137,081 | $3.35 |
| Q4 2022 | +120,376 | Add 394.52% | 150,888 | $4.81 |
| Q3 2022 | -77,785 | Reduce 71.83% | 30,512 | $5.70 |
| Q2 2022 | -173,178 | Reduce 61.53% | 108,297 | $7.10 |
| Q1 2022 | +281,475 | New Buy | 281,475 | $7.22 |
Cliff Asness's Atea Pharmaceuticals Investment FAQs
Cliff Asness first purchased Atea Pharmaceuticals, Inc. (AVIR) in Q1 2022, acquiring 281,475 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Atea Pharmaceuticals, Inc. (AVIR) for 14 quarters since Q1 2022.
Cliff Asness's largest addition to Atea Pharmaceuticals, Inc. (AVIR) was in Q1 2022, adding 281,475 shares worth $2.03 M.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 247,710 shares of Atea Pharmaceuticals, Inc. (AVIR), valued at approximately $1.15 M.
As of the Q2 2026 filing, Atea Pharmaceuticals, Inc. (AVIR) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Atea Pharmaceuticals, Inc. (AVIR) was 281,475 shares, as reported at the end of Q1 2022.